Recursion Pharmaceuticals Inc (RXRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Recursion Pharmaceuticals Inc stock (RXRX) is currently trading at $3.17. Recursion Pharmaceuticals Inc PS ratio (Price-to-Sales) is 22.42. Analyst consensus price target for RXRX is $6.71. WallStSmart rates RXRX as Sell.
- RXRX PE ratio analysis and historical PE chart
- RXRX PS ratio (Price-to-Sales) history and trend
- RXRX intrinsic value — DCF, Graham Number, EPV models
- RXRX stock price prediction 2025 2026 2027 2028 2029 2030
- RXRX fair value vs current price
- RXRX insider transactions and insider buying
- Is RXRX undervalued or overvalued?
- Recursion Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- RXRX Piotroski F-Score and Altman Z-Score
- RXRX analyst price target and Smart Rating
Recursion Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Recursion Pharmaceuticals Inc (RXRX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Recursion Pharmaceuticals Inc (RXRX) Key Strengths (3)
Revenue surging 682.00% year-over-year
Trading at 1.52x book value, attractively priced
64.43% held by institutions, strong professional interest
Supporting Valuation Data
Recursion Pharmaceuticals Inc (RXRX) Areas to Watch (4)
Company is destroying shareholder value
Losing money on operations
Very expensive at 22.4x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Recursion Pharmaceuticals Inc (RXRX) Detailed Analysis Report
Overall Assessment
This company scores 32/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 3 register as strengths (avg 8.7/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.52) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 682.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (22.42) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -59.50%, Operating Margin at -328.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -59.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 682.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RXRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RXRX's Price-to-Sales ratio of 22.42x sits near its historical average of 24.02x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 12% below its historical high of 25.62x set in Mar 2026, and 0% above its historical low of 22.42x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~25.6x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Recursion Pharmaceuticals Inc (RXRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Recursion Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 75M with 682% growth year-over-year.
Key Findings
Revenue growing at 682% YoY, reaching 75M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 112% of revenue (83M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -47M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Recursion Pharmaceuticals Inc maintain 682%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Recursion Pharmaceuticals Inc.
Bottom Line
Recursion Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 682% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(41 last 3 months)
| Insider | Type | Shares |
|---|---|---|
TAYLOR, BEN R Chief Financial Officer | Sell | -7,956 |
| Insider | Type | Shares |
|---|---|---|
TAYLOR, BEN R Chief Financial Officer | Sell | -7,075 |
| Insider | Type | Shares |
|---|---|---|
BORGESON, BLAKE Director | Sell | -170,000 |
| Insider | Type | Shares |
|---|---|---|
TAYLOR, BEN R Chief Financial Officer | Sell | -13,426 |
| Insider | Type | Shares |
|---|---|---|
BORGESON, BLAKE Director | Sell | -220,000 |
| Insider | Type | Shares |
|---|---|---|
BORGESON, BLAKE Director | Sell | -220,000 |
| Insider | Type | Shares |
|---|---|---|
TAYLOR, BEN R Chief Financial Officer | Sell | -21,383 |
Data sourced from SEC Form 4 filings
Last updated: 10:11:40 AM
About Recursion Pharmaceuticals Inc(RXRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is headquartered in Salt Lake City, Utah.